left atrial appendage, atrial fibrillation, minimally invasive cardiac surgery, AtriClip, left atrial appendage exclusion Stroke remains the most devastating complication in patients with atrial fibrillation (AF). Indeed, the stroke rate for these patients is 5% per year, and 35% of patients with AF will experience a stroke over the course of their lifetime. The left atrial appendage (LAA) is known to be the source of over 90% of cardiac thromboemboli and stroke, and therefore, it has become the focus for primary stroke prevention in patients with AF. [1] [2] [3] In the absence of persistently effective anti-arrhythmic drugs, medical therapy has revolved around the use of oral anticoagulants, balancing the risk between catastrophic bleeding and thromboembolism to decrease stroke, not to mention the adverse effect on quality of life. Additionally, numerous methods have been described to mechanically exclude the LAA in patients with AF. However, it is important to understand what constitutes a successfully excluded appendage. Failure of complete exclusion is considered when there is residual flow in an appendage that has been closed by a percutaneous or surgical method or when there is a remnant endocardial pouch of 1 cm or greater in depth or there is exposed endocardial trabeculae. The advances in technology and technique have expanded the options to treat these patients who are at risk for thromboembolic events.
site exclusion of the LAA at the time of concomitant cardiac surgery as a class IIA recommendation. 12 Despite these data adoption is not complete. As with everything, technique matters. Numerous surgical methods have been described, such as amputation and epicardial suture closure, endocardial suture ligation and staple ligation. However, reliability is a concern and a significant percentage of these approaches are known to result in incomplete closure. Additionally, epicardial excision and oversewing or endocardial closure can be time consuming, technically demanding, and associated with bleeding and injury to nearby coronary vessels. In a review of their surgical experience with 137 patients, Kanderian et al. found that only 40% of patients had complete closure. The endocardial suture technique had the highest residual flow rate at 61% and the epicardial staple ligation technique had the lowest success rate at 0%! 13 In a prospective randomized trial of these 3 techniques with long-term transesophageal echo (TEE) follow-up, the overall failure rate was a surprising 57%! 14 While successful exclusion can occur with these techniques, meticulous attention to detail is essential to obtain complete closure, especially with an excision technique to ensure that the LAA is amputated at the true base to eliminate the possibility of a residual pouch. 15 To improve efficacy and reliability while simplifying the technical aspects of the procedure, other surgically applied devices have been developed such as the AtriClip (AtriCure Inc., Mason, OH, United States). This device is a self-closing, surgically implanted epicardial LAA exclusion device that can be applied through a sternotomy. Additionally, because of its long-shafted construction, it is also ideally suited for minimally invasive approaches, either right thoracotomy, robotically or thoracoscopically, offering concomitant and stand-alone applications.
A closed or open-ended device is available and given the pure epicardial position anticoagulation may not be necessary. It is relatively quick to apply and extremely effective. Care must be taken to ensure that the clip is positioned at the true base of the appendage to ensure that it is incorporated in a consistent manner to avoid a residual pouch and incomplete closure ( Fig. 2 ). 16 Successful exclusion has been reported in up to 98.4% of patients at 1 year with no devicerelated complications. 17 In a large multicenter study of over 200 patients who underwent exclusion with an AtriClip at the time of thoracoscopic ablation, the freedom from cerebrovascular events was 99.1%. 16 In addition, as an added benefit to mechanical exclusion, the residual fibrosis that forms from tissue necrosis due to the clip arm pressure on the myocardium has also been shown to electrically isolate the LAA and thereby eliminates a potential source of AF recurrence. 18, 19 Furthermore, the results of the ATLAS trial demonstrated a significantly lower incidence of cerebrovascular events in patients without AF who underwent LAA exclusion at the time of cardiac surgery. 20 It is important to understand the advantages and disadvantages of the current methods when deciding what to offer patients and when one approach may be preferred over the other (Table 1 ). More studies are necessary to define the best devices and procedures. We are awaiting the data expected from the ongoing Left Atrial Appendage Occlusion Study III in which 4,700 cardiac surgery patients with pre-operative AF are randomized to LAA closure vs. no closure at the time of surgery with 4 years of planned follow-up and a primary endpoint of stroke or systemic embolism. However, randomized trials comparing percutaneous to surgical closure techniques even as a stand-alone procedure are required to determine superior effectiveness as well as completeness of closure. Additionally, more data are needed to understand the role of anticoagulation following complete closure of the LAA in this patient population. In the surgical literature, Dr Cox reported a perioperative and long-term neurological event rate of <1% following exclusion of the LAA at the time of a maze procedure for AF. These excellent results include 46% of patients who never anticoagulated after surgery. 9 The need for this type of data is especially relevant given the known lack of compliance with anticoagulation in AF patients. 21 Moving forward, expanded utilization of this technology and technique will become more applicable thereby offering increased options to a broader patient population. More and more patients are being evaluated for a Watchman procedure; however, a not so insignificant number of these patients will be ineligible for implantation due to anatomic reasons or an absolute contraindication to anticoagulation. Considering the increase in expertise by excluding the appendage, these patients should be referred for minimally invasive LAA exclusion with or without ablation to reduce stroke risk. Additionally, in the scenario of a dislodged Watchman or mispositioned device, an epicardial clip procedure may be an option to close the appendage and discontinue anticoagulation as indicated. Ideally, collaboration with an electrophysiologist and/or interventionalist is necessary to create a multidisciplinary approach and specifically tailor the best approach for each patient. At the University of Michigan, we have been able to do this with great success with the benefit of offering expanded options to more patients.
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